Introduction
============

Home blood pressure (HBP) monitoring is useful in the diagnosis and treatment of hypertension and has been shown to have a greater prognostic value than clinic blood pressure (CBP) monitoring.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)^[@bib8]^ and the European Society of Hypertension--European Society of Cardiology guidelines^[@bib9]^ recommend using the average of two HBP measurements obtained on one occasion to determine a person's blood pressure. The prognostic values of the first and second HBP measurements obtained on one occasion at baseline have been investigated in the Finn-Home study^[@bib10]^ and the Didima study.^[@bib11]^ However, the prognostic value of the first, second and the averaged HBP during the follow-up period is unclear. Moreover, the second measurement of systolic HBP is often lower compared with the first,^[@bib12],\ [@bib13]^ but the prognostic value of the difference between these two measurements has yet to be clarified.

The HBP measurement with Olmesartan-Naive patients to Establish Standard Target blood pressure (HONEST) study is a large-scale, prospective, observational study performed to investigate the relationship between morning HBP and CBP during the follow-up period and the risk of cardiovascular events in \>20 000 Japanese patients with hypertension.^[@bib12],\ [@bib14]^ A primary analysis of the data from the HONEST study has shown that cardiovascular risk is increased in patients with a morning home systolic blood pressure (MHSBP) of ⩾145 mm Hg, even when CBP is controlled.^[@bib1]^ This finding emphasizes the importance of HBP monitoring in clinical practice.

In the present analysis, we used the data from the HONEST study to determine the prognostic value of the first and second HBP measurements obtained on one occasion, and their average value, in patients receiving treatment for hypertension. We also investigated the relationship of the difference between the first and second MHSBP (ΔMHSBP) and the patient's prognosis. We used measurements of MHSBP because it is the strongest indicator of common cardiovascular events.^[@bib15]^

Methods
=======

Study design
------------

HONEST is a large-scale, prospective, observational study with a 2-year follow-up period. The study population comprised patients receiving olmesartan-based treatment for hypertension. The study is registered at the UMIN Clinical Trials Registry (<http://www.umin.ac.jp/ctr/index.htm>) with the unique trial number of UMIN000002567.

The study protocol was approved by the Ethical Committee of Daiichi Sankyo and the research ethics committees of the participating institutions, at their discretion. The study was approved by the Ministry of Health, Labor and Welfare of Japan before it began and conforms to the country's pharmaceutical affairs laws. In compliance with Good Post-marketing Study Practices in Japan, the study was performed at registered medical institutions.

The aims and the protocol of the HONEST study have been reported previously.^[@bib12]^ Olmesartan-naive patients with essential hypertension who had their morning HBP recorded for ⩾2 days and their CBP recorded for ⩾1 day in the 28 days before starting olmesartan were eligible to participate. The patients were enrolled in the study after providing written informed consent and being prescribed olmesartan. Those who had had a cardiovascular event in the previous 6 months were excluded, as well as those with a planned cardiovascular intervention or serious hepatic or renal dysfunction. The primary end point was a composite of cerebrovascular events (cerebral infarction, intracerebral hemorrhage, subarachnoid hemorrhage and unclassified stroke), cardiac events (myocardial infarction and coronary revascularization procedures for angina pectoris) and sudden death. Follow-up was maintained for patients who discontinued treatment with olmesartan.

HBP measurements
----------------

Patients who already possessed a cuff oscillometric device were enrolled in the study. All such devices available in Japan have been validated and approved by the Ministry of Health, Labor and Welfare. The devices also comply with the Association for the Advancement of Medical Instrumentation^[@bib16]^ or European standards.^[@bib17]^ At the time that informed consent was obtained, the patients were asked to measure their HBP two times in the morning (within 1 h of waking, after urination, before taking any morning medications, before breakfast and after 1--2 min of rest in a sitting position) and two times at bedtime (after 1--2 min of rest in a sitting position), according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).^[@bib18]^ Participating patients in the present study received a pocket diary to record their HBP. Physicians instructed the patients to report their HBP obtained on the prespecified measurement day and the day before (when this was not possible, on 2 days in the week before or after the prespecified measurement day). Details of the timing and frequency of measurements were indicated in the informed consent form and the pocket diary.

During the follow-up, the HBP was measured at 1, 4 and 16 weeks and at 6, 12, 18 and 24 months. In principle, patients reported their HBP that were measured two times in the morning and two times at bedtime on two different days for each of these measurement points. When there were several HBP measurements at each measurement time, the physicians gave priority to any measurements reported for 2 days, for which both the first and second measurements of the morning and evening were available. In addition, measurements taken on days close to the prespecified measurement day were also used; however, when the differences in days from the prespecified measurement day were the same, the measurement of the day before the other was used. For each HBP variable, namely the first, second and averaged MHSBP measurements, and ΔMHSBP, the mean value over 2 days (provided the necessary data were available) was calculated for each measurement point. Moreover, the mean HBP values for the maximum of the seven measured time points (1, 4 and 16 weeks and 6, 12, 18 and 24 months) during the follow-up period were further averaged and used in the analyses of hazard ratios (HRs).

Statistical analysis
--------------------

The analysis set comprised eligible patients who had received olmesartan at least once.

To determine their prognostic value for cardiovascular events, HRs for each 1 mmHg increase in the first, second and averaged MHSBP during the follow-up period were estimated using the Cox proportional hazards model, which was adjusted for sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease and smoking status. Furthermore, multivariate generalized additive models adjusted for risk factors as mentioned above with a spline function of three degrees of freedom were used to investigate potential nonlinear relationships between the ΔMHSBP during the follow-up as continuous variables as well as the incidence of cardiovascular events.

Subsequently, to investigate the relationship between ΔMHSBP and prognosis, we used a multivariate Cox proportional hazards model adjusted for MHSBP during the follow-up period and other risk factors as mentioned above (i.e., sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease and smoking status) to compare hazards for the three groups of patients stratified by ΔMHSBP: \<−5 , ⩾−5 to \<5 and ⩾5 mm Hg.

To further investigate the relationships between ΔMHSBP and the average value of these two measurements, we compared hazards for the six groups of patients classified first by ΔMHSBP (large difference, \<−5 or ⩾5 mm Hg; small difference, ⩾−5 to \<5 mm Hg) and second by the averaged MHSBP (\<125, ⩾125 to \<145 and ⩾145 mm Hg) adjusted for risk factors as mentioned above (i.e., sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease and smoking status). The cutoff values for MHSBP of 125 and 145 mm Hg were chosen based on the findings in the main HONEST study,^[@bib1]^ in which cardiovascular risk significantly increased at an MHSBP of ⩾145 mm Hg and was at a minimum at an MHSBP of 124 mm Hg during the follow-up period.

All statistical tests were two-sided, using a significance level of *P*\<0.05. SAS release 9.2 software (SAS Institute, Cary, NC, USA) was used for all statistical analyses.

Results
=======

Data were collected from 22 298 of the 22 373 patients enrolled in the study. After eliminating data from patients who met the exclusion criteria, data from 21 591 patients were included in the analysis. The mean age of the patients enrolled in the study was 64.9±11.9 years; 51% of the patients were female; 50% of the patients received prior antihypertensive treatment; 45% of patients had dyslipidemia; 21% of patients had diabetes mellitus; 20% of patients had chronic kidney disease; and 11% of patients had a history of cerebral or cardiovascular disease. The mean follow-up period was 2.02 years.

The first, second and averaged MHSBP were 151.6±16.4 mm Hg (*n*=21 587), 150.1±16.2 mm Hg (*n*=7730) and 151.2±16.3 mm Hg (*n*=21 588), respectively, at baseline, and 135.8±10.9 mm Hg (*n*=20 999), 133.8±11.1 mm Hg (*n*=18 251) and 135.2±10.8 mm Hg (*n*=21 001), respectively, during the follow-up period. In patients whose first and second MHSBP values were both available (*n*=18 249), the first, second and averaged MHSBP during the follow-up period were 135.7±10.8, 133.8±11.1 and 135.1±10.6 mm Hg, respectively. In the present analysis of the average value, in accordance with JSH 2014,^[@bib8]^ we used the average of the two HBP measurements obtained on each occasion, if available; if these measurements were not available, a single measurement was used. A total of 280 patients reached the primary end point (incidence, 6.46/1000 patient-years).

Hazards for cardiovascular events increased significantly with each 1 mmHg increase in the first, second and averaged MHSBP during the follow-up period; the HR (95% confidence interval (95% CI)) for each was 1.039 (1.028--1.049), 1.038 (1.027--1.049) and 1.039 (1.029--1.049), respectively.

The analysis using a spline regression model showed that relative risk increased proportionally with ΔMHSBP ([Figure 1](#fig1){ref-type="fig"}). A mean of 4.6 individual calculations (maximum, 7) using data from separate measurement points was used to generate the ΔMHSBP value for each patient.

[Table 1](#tbl1){ref-type="table"} shows the baseline characteristics of the three groups of patients classified by ΔMHSBP; mean age was significantly higher in the two groups of patients with a large difference (\<−5 and ⩾5 mm Hg) compared with the group with a small difference (⩾−5 to \<5 mm Hg). The patients with ΔMHSBP of \<−5 mm Hg were significantly more likely to have had a history of cerebrovascular or cardiovascular disease or diabetes mellitus. The patients with ΔMHSBP of ⩾5 mm Hg were significantly more likely to be women, to have had dyslipidemia or previous antihypertensive treatment and to have been receiving concomitant drugs at study entry and were less likely to be current smokers and regular alcohol drinkers.

The averaged MHSBP of patients with a ΔMHSBP of \<−5, ⩾−5 to \<5 and ⩾5 mm Hg were 151.0±16.9, 150.6±16.1 and 151.9±16.4 mm Hg, respectively, at baseline, and 136.9±13.5, 134.7±10.3 and 136.3±11.4 mm Hg, respectively, during the follow-up period.

Hazards (adjusted for cardiovascular risk factors and the averaged MHSBP during the follow-up period) were significantly increased for patients with a large ΔMHSBP compared with for those with a small ΔMHSBP ([Figure 2](#fig2){ref-type="fig"}).

A comparison of the six groups of patients classified by the ΔMHSBP and the averaged MHSBP shows significantly increased hazards for patients with an averaged MHSBP of ⩾145 mm Hg in the group with a small ΔMHSBP, and for those with an averaged MHSBP of ⩾125 mm Hg in the group with a large ΔMHSBP compared with that in the group with an averaged MHSBP of \<125 mmHg and a small ΔMHSBP ([Figure 3](#fig3){ref-type="fig"}). With a cutoff value for MHSBP of 135 mm Hg (as consistent with the threshold in JSH 2014), the hazards were higher in patients with an averaged MHSBP of ⩾135 mm Hg and a small ΔMHSBP (HR: 1.85; 95% CI: 1.32--2.61)), those with an averaged MHSBP of \<135 mm Hg and a large ΔMHSBP (HR: 2.17; 95% CI: 1.35--3.49) and those with an averaged MHSBP of ⩾135 mm Hg and a large ΔMHSBP (HRs: 2.50; 95% CI: 1.65--3.80), compared with those with an averaged MHSBP of \<135 mm Hg and a small ΔMHSBP.

Discussion
==========

The results of the present analysis show that the first and second measurements of MHSBP obtained on one occasion and their average value during the follow-up period have similar prognostic value for the assessment of cardiovascular risk. Prognosis is worse for patients with a large difference between the first and second MHSBP measurements.

Prognostic value for each 1 mmHg increase in each HBP variable
--------------------------------------------------------------

In the HONEST study, as in the Finn-Home study^[@bib10]^ and the Didima study,^[@bib11]^ the HBP was measured two times on single occasions. In the HONEST study, the difference between the first and second measurements of MHSBP was small (⩾−5 to \<5 mm Hg) in \~75% of patients, and we found a similar prognostic value between the first and second MHSBP measurements during the follow-up period. In the Finn-Home study, participants from the general population had two HBP measurements taken in both the morning and in the evening for 7 consecutive days at baseline; the relative hazards (95% CI) for each 1 mmHg increase in the first and second SBP measurement were 1.020 (95% CI: 1.011--1.028) and 1.022 (95% CI: 1.014--1.031), respectively.^[@bib10]^ In the Didima study, participants were also enrolled from the general population, and the HBP was measured in the same way for 3 days at baseline; HRs per 1 mmHg increase were similar for the first and second measurements (1.033 and 1.035, respectively), although the first measurement was on average 3.5 mm Hg higher compared with the second.^[@bib11]^

Prognostic value of the difference between the first and second measurements
----------------------------------------------------------------------------

In the past few years, the relationship between BP variability and cardiovascular risk has been the focus of several clinical studies. A morning surge in BP has been reported to predict cardiovascular events.^[@bib19]^ Associations between prognosis and circadian variability,^[@bib20]^ day-to-day variability^[@bib21],\ [@bib22]^ and visit-to-visit variability have also been reported.^[@bib23]^

Differences between the first and subsequent BP measurements on one occasion may indicate a type of short-term variability. In the Finn-Home study, the s.d. of the difference between the first and second HBP measurements was found to predict cardiovascular events.^[@bib21]^ However, no study has been performed to investigate the relationship among the actual differences between the first and subsequent HBP measurements and cardiovascular events.

In the present analysis, we considered ±5 mm Hg to be the cutoff value for clinically significant changes based on the results from the spline regression model using continuous variables of ΔMHSBP during the follow-up period and the incidence of cardiovascular events. We found that, while ΔMHSBP ⩾--5 to \<5 mm Hg had very little effect on cardiovascular risk, the risk increased for an ΔMHSBP of \<--5 or \>5 mm Hg ([Figure 1](#fig1){ref-type="fig"}).

Subsequently, using the cutoff value of ±5 mm Hg, to compare hazards we classified patients into three groups by the ΔMHSBP. Consequently, we found that the difference between the first and second HBP measurements obtained on one occasion was a cardiovascular risk factor independent of actual HBP values.

With respect to baseline characteristics, patients with a large ΔMHSBP (ΔMHSBP \<--5 or \>5 mm Hg) tended to have a higher average age compared with patients with a small difference (⩾−5 to \<5 mm Hg).

In elderly patients, whose blood vessel elasticity is often reduced by arteriosclerosis, increased BP variability is an independent predictor of cardiovascular events.^[@bib24]^ Elderly patients also often have a history of various diseases and complications, which may also contribute to their overall high risk of cardiovascular disease. The present analysis was adjusted for sex, age, history of cardiovascular diseases, smoking status, risk complications and, most importantly, the mean MHSBP during the follow-up period, which is the greatest cardiovascular risk factor. Cardiovascular risk was significantly increased in patients with a large ΔMHSBP, but was independent of actual MHSBP. We also conducted analyses of evening home SBP by using a spline regression model and a Cox regression model, and similar results were observed (data not shown).

A subanalysis of the J-HOP study enrolling 4149 Japanese patients with cardiovascular risk factors investigated the relationship among the differences between the first and second or third HBP measurements and the levels of various indicators of target organ damage.^[@bib25]^ In that study, patients whose second and third measurements were higher compared with the first measurement were more likely to have diabetes or impaired glucose tolerance, had a higher B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels and had a lower estimated glomerular filtration rate compared with those in the reference group (quintile median). Moreover, patients with the greatest decreases in subsequent measurements also had higher N-terminal pro-B-type natriuretic peptide levels compared with those in the reference group. In the present study, we also found that patients with a ΔMHSBP of \<−5 mm Hg were more likely to have a history of cerebro- or cardiovascular disease as well as complications of diabetes mellitus or chronic kidney disease, which may have influenced their prognosis. Among the five serial CBP measurements, Velasco *et al.*^[@bib26]^ reported that the first CBP reading had prognostic significance. Participants were categorized into four groups based on the first CBP and the averaged third to fifth CBP readings: 1, normal 1st CBP and normal averaged 3rd to 5th CBP; 2, high 1st CBP and normal averaged 3rd to 5th CBP; 3, normal 1st CBP and high averaged 3rd to 5th CBP and 4, high 1st CBP and high averaged 3rd to 5th CBP in their study. They found a higher cumulative incidence for cardiovascular events in participants with high 1st CBP and normal averaged 3rd to 5th CBP compared with those with normal 1st CBP and normal averaged 3rd to 5th CBP during the 9.4 years of follow-up. They also reported that Δ 1st CBP and the averaged 3rd to 5th CBP readings were associated with cardiovascular events independent of the averaged 3rd to 5th CBP readings.

Our findings demonstrate a higher cardiovascular risk in patients with a large ΔMHSBP compared with patients with a small ΔMHSBP. Specifically, those with a higher averaged MHSBP indicated the importance of using the averaged HBP values and the differences between the first and second HBP measurements as predictors of cardiovascular events.

Limitations
-----------

The present study has some limitations. First, the HONEST study is an observational study designed to reflect real-world clinical practice. Therefore, patients were not blinded to their treatment and there was no control group. No BP targets were specified, and BP control was used at the discretion of the attending physicians.

Second, the present study enrolled patients who had already owned cuff oscillometric devices to measure their HBP, and no specific types of device were used. However, HBP-measuring devices available in Japan have been validated and approved by the Ministry of Health, Labor and Welfare of Japan and are in accordance with United States (Association for the Advancement of Medical Instrumentation)^[@bib16]^ or European standards.^[@bib17]^ Therefore, we believe the influence due to the use of different devices is limited.

Third, in the present study, only 2 days of HBP values were used for each measurement point to reduce the burden on patients and physicians in collecting these measurements. To minimize the potential for selection bias, detailed procedures for measuring and reporting HBP values were defined in the study protocol. Nevertheless, the possibility of biased reporting cannot be excluded completely. Although it is generally accepted that potential selection bias is reduced with an increase in sample size, the present study is limited by the nature of its design (observational study).

Finally, the mean follow-up period of the present study was relatively short (2.02 years).

Conclusion
==========

First, second and averaged MHSBP during the follow-up period have similar prognostic values. Patients with a large ΔMHSBP have a worse prognosis than those with a small ΔMHSBP. Furthermore, cardiovascular risk is particularly increased in patients with both a large ΔMHSBP and a higher averaged MHSBP. Therefore, we recommend that the HBP be measured twice on one occasion and that the average value of the two measurements be used to monitor patients, with particular attention paid to those with a large ΔMHSBP.
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![The relationship between ΔMHSBP during the follow-up period and cardiovascular risk (continuous evaluation by spline regression analysis, adjusted for sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease and smoking status). ΔMHSBP, the difference between the first and second measurements of the home systolic blood pressure taken in the morning.](hr201699f1){#fig1}

![The relationship between ΔMHSBP during the follow-up period and cardiovascular risk (reference, ΔMHSBP ⩾−5 to \<5 mm Hg). The hazard ratio for cardiovascular events was adjusted for sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease, smoking status and the averaged MHSBP during the follow-up period. CI, confidence interval; ΔMHSBP, the difference between the first and second measurements of the home systolic blood pressure taken in the morning.](hr201699f2){#fig2}

![Cardiovascular risk stratified by ΔMHSBP during the follow-up period and the averaged MHSBP. The hazard ratio for cardiovascular events was adjusted for sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of cardiovascular disease and smoking status. ΔMHSBP, the difference between the first and second measurements of the home systolic blood pressure taken in the morning.](hr201699f3){#fig3}

###### Baseline characteristics of patients in the HONEST study

                                                                      *ΔMHSBP (mm Hg)*   *P*-value[a](#t1-fn2){ref-type="fn"} (*vs.* *ΔMHSBP ⩾−5 to \<5 mm Hg)*                                                      
  ------------------------------------------------------------------ ------------------ ------------------------------------------------------------------------ ------------- ------------------------------------- -------------------------------------
  No. of patients                                                           356                                          14 269                                      3624                       ---                                   ---
  Women                                                                  172 (48.3)                                   6983 (48.9)                                 2097 (57.9)                  0.82                   \<0.0001[b](#t1-fn3){ref-type="fn"}
  Mean age (years)                                                       66.3±12.0                                     64.4±11.9                                   66.3±11.1     0.004[b](#t1-fn3){ref-type="fn"}     \<0.0001[b](#t1-fn3){ref-type="fn"}
  Body mass index (kg m^−2^)                                              24.4±4.0                                      24.3±3.6                                   24.2±3.7                    0.67                                  0.46
  Hypertension duration (years)                                           4.4±4.5                                       5.0±4.4                                     5.1±4.5                    0.03                                  0.85
                                                                                                                                                                                                                                        
  *Disease history*                                                                                                                                                                                                  
   Cerebro- or cardiovascular disease                                    61 (17.1)                                    1426 (10.0)                                 385 (10.6)    \<0.0001[b](#t1-fn3){ref-type="fn"}                  0.24
   Cerebrovascular disease                                               41 (11.5)                                     862 (6.0)                                   244 (6.7)    \<0.0001[b](#t1-fn3){ref-type="fn"}                  0.12
   Cardiovascular disease                                                 25 (7.0)                                     651 (4.6)                                   165 (4.6)                   0.03                                  1.00
                                                                                                                                                                                                                                        
  *Complications*                                                                                                                                                                                                    
   Dyslipidemia                                                          168 (47.2)                                   6405 (44.9)                                 1735 (47.9)                  0.39                    0.001[b](#t1-fn3){ref-type="fn"}
   Diabetes mellitus                                                     113 (31.7)                                   2926 (20.5)                                 727 (20.1)    \<0.0001[b](#t1-fn3){ref-type="fn"}                  0.55
   Chronic kidney disease                                                88 (24.7)                                    2909 (20.4)                                 705 (19.5)                   0.04                                  0.19
  Current smokers                                                        48 (13.5)                                    1731 (12.1)                                 380 (10.5)                   0.57                   \<0.0001[b](#t1-fn3){ref-type="fn"}
  Regular alcohol drinkers                                               59 (16.6)                                    2343 (16.4)                                 549 (15.1)                   0.08                   \<0.0001[b](#t1-fn3){ref-type="fn"}
  Previous antihypertensive drug use                                     185 (52.0)                                   7206 (50.5)                                 1941 (53.6)                  0.58                    0.001[b](#t1-fn3){ref-type="fn"}
  Antihypertensive drug used at study entry (excluding olmesartan)       157 (44.1)                                   5519 (38.7)                                 1509 (41.6)                  0.04                    0.001[b](#t1-fn3){ref-type="fn"}

Abbreviations: HBP, home blood pressure; HONEST, HBP measurement with Olmesartan-Naive patients to Establish Standard Target blood pressure; ΔMHSBP, the difference between the first and second measurements of morning home systolic blood pressure during the follow-up period.

*χ*^2^ Test for categorical data and *t*-test for continuous data. Tested for other than missing cases.

Significant result (significant level: \<0.05/3 by Bonferroni correction).
